We understand that people with cancer are worried about coronavirus. Here is the latest guidance. We will update it regularly.

Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 2

Cover image of 'Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public'

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public (January 2020)

National Institute for Health and Care Excellence (NICE)

Information about palbociclib (Ibrance), with fulvestrant, which is available through the Cancer Drugs Fund, and which may be used to treat hormone receptor-positive, HER2-negative, advanced breast cancer.

Cover image of 'Palbociclib (Ibrance ®) (Polish)'

Palbociclib (Ibrance ®) (Polish) (June 2018)

Macmillan Cancer Support

Palbociclib (Ibrance®) is a targeted therapy drug used to treat breast cancer that is oestrogen receptor positive and HER 2 negative. This factsheet describes what it is, how it is given, and possible side effects. 

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm